Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALS20 Gene Therapy in Transfusion-Dependent Beta Thalassemia
NCT06364774Phase 2Active, not recruiting
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Lentiviral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of ALS20 in beta thalassemia, sponsored by Children's Hospital of Philadelphia. Started Apr 2025; status: active, not recruiting.
02
Drugs
ALS20
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT06364774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364774.